1887
  1. Home
  2. Eurosurveillance
  3. Volume 21, Issue 21, 26/May/2016
  4. Article
Surveillance and outbreak report Open Access
Like 0
Download

Abstract

Concurrent analysis of antibiotic resistance of colonising and invasive gives a more accurate picture than looking at either of them separately. Therefore, we analysed 2,129 non-invasive and 10,996 invasive pneumococcal isolates from Switzerland from 2004 to 2014, which spans the time before and after the introduction of the heptavalent (PCV7) and 13-valent (PCV13) conjugated pneumococcal polysaccharide vaccines. Serotype/serogroup information was linked with all antibiotic resistance profiles. During the study period, the proportion of non-susceptible non-invasive and invasive isolates significantly decreased for penicillin, ceftriaxone, erythromycin and trimethoprim/sulfamethoxazole (TMP-SMX). This was most apparent in non-invasive isolates from study subjects younger than five years (penicillin (p = 0.006), erythromycin (p = 0.01) and TMP-SMX (p = 0.002)). Resistant serotypes/serogroups included in PCV7 and/or PCV13 decreased and were replaced by non-PCV13 serotypes (6C and 15B/C). Serotype/serogroup-specific antibiotic resistance rates were comparable between invasive and non-invasive isolates. Adjusted odds ratios of serotype/serogroup-specific penicillin resistance were significantly higher in the west of Switzerland for serotype 6B (1.8; 95% confidence interval (CI): 1.4–4.8), 9V (3.4; 95% CI: 2.0–5.7), 14 (5.3; 95% CI: 3.8–7.5), 19A (2.2; 95% CI: 1.6–3.1) and 19F (3.1; 95% CI: 2.1–4.6), probably due to variations in the antibiotic consumption.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.21.30239
2016-05-26
2024-11-15
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2016.21.21.30239
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/21/eurosurv-21-30239-3.html?itemId=/content/10.2807/1560-7917.ES.2016.21.21.30239&mimeType=html&fmt=ahah

References

  1. Aebi C, Duppenthaler A. [Antimicrobial resistance--consequences for ambulatory treatment of infections in children]. Ther Umsch. 2002;59(1):46-50. German.  https://doi.org/10.1024/0040-5930.59.1.46  PMID: 11851047 
  2. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90(2):223-9.  https://doi.org/10.2105/AJPH.90.2.223  PMID: 10667183 
  3. Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies - what are we missing? Nat Rev Microbiol. 2004;2(12):979-83.  https://doi.org/10.1038/nrmicro1047  PMID: 15550943 
  4. Meichtry J, Born R, Küffer M, Zwahlen M, Albrich WC, Brugger SD, et al. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study. Vaccine. 2014;32(40):5185-91.  https://doi.org/10.1016/j.vaccine.2014.07.060  PMID: 25077419 
  5. Song JH, Dagan R, Klugman KP, Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine. 2012;30(17):2728-37.  https://doi.org/10.1016/j.vaccine.2012.01.091  PMID: 22330126 
  6. Kronenberg A, Zucs P, Droz S, Mühlemann K. Distribution and invasiveness of Streptococcus pneumoniae serotypes in Switzerland, a country with low antibiotic selection pressure, from 2001 to 2004. J Clin Microbiol. 2006;44(6):2032-8.  https://doi.org/10.1128/JCM.00275-06  PMID: 16757594 
  7. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(Suppl 2):S81-93.
  8. Mühlemann K, Matter HC, Täuber MG, Bodmer TSentinel Working Group. Nationwide surveillance of nasopharyngeal Streptococcus pneumoniae isolates from children with respiratory infection, Switzerland, 1998-1999. J Infect Dis. 2003;187(4):589-96.  https://doi.org/10.1086/367994  PMID: 12599075 
  9. Bundesamt für Gesundheit (BAG). Repräsentativität des Sentinella-Ärztekollektivs. [Representativeness of the collective of sentinel physicians]. BAG Bulletin. 2001;37(01):680. German. Available from: http://www.bag.admin.ch/dokumentation/publikationen/01435/01801/index.html?lang=de&download=NHzLpZig7t,lnp6I0NTU042l2Z6ln1acy4Zn4Z2qZpnO2Yuq2Z6gpJCEdX56fWym162dpYbUzd,Gpd6emK2Oz9aGodetmqaN19XI2IdvoaCUZ,s-
  10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, twenty-second informational supplement. Document M100-S22. Wayne: CLSI; 2012
  11. Goossens H, Ferech M, Vander Stichele R, Elseviers MESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579-87.  https://doi.org/10.1016/S0140-6736(05)70799-6  PMID: 15708101 
  12. Kempf M, Varon E, Lepoutre A, Gravet A, Baraduc R, Brun M, et al. Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001-2011 survey by the French Pneumococcal Network. Clin Microbiol Infect. 2015;21(1):35-42.  https://doi.org/10.1016/j.cmi.2014.08.009  PMID: 25636925 
  13. Filippini M, Masiero G, Moschetti K. Socioeconomic determinants of regional differences in outpatient antibiotic consumption: evidence from Switzerland. Health Policy. 2006;78(1):77-92.  https://doi.org/10.1016/j.healthpol.2005.09.009  PMID: 16290129 
  14. Imöhl M, Reinert RR, Mutscher C, van der Linden M. Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008. BMC Microbiol. 2010;10(1):299.  https://doi.org/10.1186/1471-2180-10-299  PMID: 21108778 
  15. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14):1455-63.  https://doi.org/10.1056/NEJMoa051642  PMID: 16598044 
  16. Hackel M, Lascols C, Bouchillon S, Hilton B, Morgenstern D, Purdy J. Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations. Vaccine. 2013;31(42):4881-7.  https://doi.org/10.1016/j.vaccine.2013.07.054  PMID: 23928466 
  17. Imöhl M, Reinert RR, van der Linden M. Serotype-specific penicillin resistance of Streptococcus pneumoniae in Germany from 1992 to 2008. Int J Med Microbiol. 2010;300(5):324-30.  https://doi.org/10.1016/j.ijmm.2009.11.004  PMID: 20071233 
  18. Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, et al. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. J Infect Dis. 2015;211(7):1144-53.  https://doi.org/10.1093/infdis/jiu576  PMID: 25355940 
  19. Bundesamt für Gesundheit (BAG). Pneumokokken-Erkrankungen. [Pneumococcal diseases]. Bern: BAG; 2013. German. Available from: http://www.bag.admin.ch/themen/medizin/00682/00684/01097/index.html?lang=it
  20. Chiba N, Morozumi M, Shouji M, Wajima T, Iwata S, Ubukata K, et al. Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010-2013. Emerg Infect Dis. 2014;20(7):1132-9.  https://doi.org/10.3201/eid2007.131485  PMID: 24960150 
  21. Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study. Vaccine. 2015;33(9):1135-42.  https://doi.org/10.1016/j.vaccine.2015.01.030  PMID: 25613717 
  22. Lambertsen LM, Harboe ZB, Konradsen HB, Christensen JJ, Hammerum AM. Non-invasive erythromycin-resistant pneumococcal isolates are more often non-susceptible to more antimicrobial agents than invasive isolates. Int J Antimicrob Agents. 2010;35(1):72-5.  https://doi.org/10.1016/j.ijantimicag.2009.09.006  PMID: 19892529 
  23. Saha SK, Baqui AH, Darmstadt GL, Ruhulamin M, Hanif M, El Arifeen S, et al. Comparison of antibiotic resistance and serotype composition of carriage and invasive pneumococci among Bangladeshi children: implications for treatment policy and vaccine formulation. J Clin Microbiol. 2003;41(12):5582-7.  https://doi.org/10.1128/JCM.41.12.5582-5587.2003  PMID: 14662944 
  24. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RNAlexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52(2):229-46.  https://doi.org/10.1093/jac/dkg321  PMID: 12865398 
  25. Beekmann SE, Heilmann KP, Richter SS, García-de-Lomas J, Doern GVGRASP Study Group. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents. 2005;25(2):148-56.  https://doi.org/10.1016/j.ijantimicag.2004.09.016  PMID: 15664485 
  26. Pérez-Trallero E, Marimón JM, Larruskain J, Alonso M, Ercibengoa M. Antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae isolates from elderly patients with pneumonia and acute exacerbation of chronic obstructive pulmonary disease. Antimicrob Agents Chemother. 2011;55(6):2729-34.  https://doi.org/10.1128/AAC.01546-10  PMID: 21402843 
  27. Kronenberg A, Koenig S, Droz S, Mühlemann K. Active surveillance of antibiotic resistance prevalence in urinary tract and skin infections in the outpatient setting. Clin Microbiol Infect. 2011;17(12):1845-51.  https://doi.org/10.1111/j.1469-0691.2011.03519.x  PMID: 21880098 
  28. Plüss-Suard C, Pannatier A, Kronenberg A, Mühlemann K, Zanetti G. Hospital antibiotic consumption in Switzerland: comparison of a multicultural country with Europe. J Hosp Infect. 2011;79(2):166-71.  https://doi.org/10.1016/j.jhin.2011.05.028  PMID: 21820207 
  29. Achermann R, Suter K, Kronenberg A, Gyger P, Mühlemann K, Zimmerli W, et al. Antibiotic use in adult outpatients in Switzerland in relation to regions, seasonality and point of care tests. Clin Microbiol Infect. 2011;17(6):855-61.  https://doi.org/10.1111/j.1469-0691.2010.03348.x  PMID: 20731682 
Serotype/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Christoph+Hauser&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hauser Christoph</a>, <a href="/search?value1=Andreas+Kronenberg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kronenberg Andreas</a>, <a href="/search?value1=Aur%C3%A9lie+Allemann&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Allemann Aurélie</a>, <a href="/search?value1=Kathrin+M%C3%BChlemann&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mühlemann Kathrin</a>, <a href="/search?value1=Markus+Hilty&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hilty Markus</a></span>. Serotype/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014. <a href="/content/ecdc">Euro Surveill.</a> 2016;21(21):pii=30239. <a href="https://doi.org/10.2807/1560-7917.ES.2016.21.21.30239" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2016.21.21.30239</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 22 Jun 2015;&nbsp;&nbsp; <span class="generated">Accepted</span>: 07 Jan 2016 </span> </p>
/content/10.2807/1560-7917.ES.2016.21.21.30239
/content/10.2807/1560-7917.ES.2016.21.21.30239
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error